Enzo Biochem Shares Outstanding 2006-2021 | ENZ

Enzo Biochem shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Enzo Biochem Annual Shares Outstanding
(Millions of Shares)
2021 48
2020 48
2019 47
2018 47
2017 46
2016 47
2015 45
2014 43
2013 40
2012 39
2011 38
2010 38
2009 38
2008 37
2007 35
2006 32
2005 33
Enzo Biochem Quarterly Shares Outstanding
(Millions of Shares)
2021-07-31 48
2021-04-30 49
2021-01-31 48
2020-10-31 48
2020-07-31 48
2020-04-30 48
2020-01-31 48
2019-10-31 48
2019-07-31 47
2019-04-30 48
2019-01-31 47
2018-10-31 47
2018-07-31 47
2018-04-30 47
2018-01-31 47
2017-10-31 47
2017-07-31 46
2017-04-30 46
2017-01-31 46
2016-10-31 46
2016-07-31 47
2016-04-30 46
2016-01-31 47
2015-10-31 46
2015-07-31 45
2015-04-30 46
2015-01-31 45
2014-10-31 45
2014-07-31 43
2014-04-30 43
2014-01-31 42
2013-10-31 41
2013-07-31 40
2013-04-30 40
2013-01-31 39
2012-10-31 39
2012-07-31 39
2012-04-30 39
2012-01-31 39
2011-10-31 39
2011-07-31 38
2011-04-30 38
2011-01-31 38
2010-10-31 38
2010-07-31 38
2010-04-30 38
2010-01-31 38
2009-10-31 38
2009-07-31 38
2009-04-30 37
2009-01-31 37
2008-10-31 37
2008-07-31 37
2008-04-30 37
2008-01-31 37
2007-10-31 37
2007-07-31 35
2007-04-30 37
2007-01-31 34
2006-10-31 32
2006-07-31 32
2006-04-30 32
2006-01-31 32
2005-10-31 32
2005-07-31 33
2005-04-30 32
2005-01-31 32
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.159B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00